US 11,701,356 B2
Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor
Nimali Piyushika Withana, Menlo Park, CA (US); Aruna Mani, San Carlos, CA (US); and Stina Mui Singel, Menlo Park, CA (US)
Assigned to GENENTECH, INC., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Dec. 17, 2019, as Appl. No. 16/716,815.
Claims priority of provisional application 62/822,556, filed on Mar. 22, 2019.
Claims priority of provisional application 62/782,116, filed on Dec. 19, 2018.
Prior Publication US 2020/0197396 A1, Jun. 25, 2020
Int. Cl. A61K 31/517 (2006.01); A61K 47/62 (2017.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/337 (2006.01); A61K 47/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 9/0019 (2013.01); A61K 31/337 (2013.01); A61K 47/62 (2017.08); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 45/06 (2013.01)] 26 Claims
 
1. A method of treating metastatic triple negative breast cancer (MTNBC) in a patient having MTNBC, the method comprising administering to the patient a combination therapy comprising:
ipatasertib;
(ii) atezolizumab; and
(iii) paclitaxel or nab-paclitaxel,
wherein said combination therapy is administered over a 28-day cycle.